Table 2.
General characteristics of the patients regarding WHO clinical severity classification.
| Variables | WHO: 3 N = 24 |
WHO: 4 N = 65 |
WHO: 5 N = 10 |
WHO: 6 N = 17 |
WHO: 7 N = 9 |
P |
|---|---|---|---|---|---|---|
| Gender, Male, % | 50 | 58.5 | 87.5 | 58.8 | 90.9 | 0.458 |
| Age, years | 74(58) | 66(73) | 77(64) | 63(20) | 67(73) | 0.379 |
| Time initial symptoms since diagnosis, days | 3.6 | 5.2 | 3.3 | 7 | 5.9 | 0.587 |
| Hypertension, % | 50 | 52.3 | 62.5 | 52.9 | 45.5 | 0.974 |
| Diabetes mellitus, % | 29.2 | 23.1 | 25 | 23.5 | 27.3 | 0.970 |
| Dyslipidemia, % | 37.5 | 23.1 | 37.3 | 35.3 | 36.4 | 0.547 |
| Cardiovascular Disease, % | 45.8 | 49.2 | 62.5 | 52.9 | 45.5 | 0.401 |
| OPCD, % | 8.3 | 20 | 0 | 11.8 | 0 | 0.195 |
| Chronic neurologic disease,%, | 45.8 | 16.9 | 12.5 | 0 | 0 | 0.001∗ |
| Hepatic disease, % | 0 | 1.5 | 0 | 0 | 0 | 0.221 |
| Renal chronic Disease, % | 12.5 | 18.5 | 25 | 11.8 | 0 | 0.290 |
| HIV, % | 0 | 0 | 10 | 5.9 | 0 | 0.954 |
| Neoplasm, % | 12.3 | 9.2 | 25 | 11.8 | 9.1 | 0.361 |
| Statins (pre-admission), % | 16.7 | 27.7 | 25 | 35.3 | 36.4 | 0.143 |
| ACE(pre-admission), % | 16.7 | 23.1 | 12.5 | 35.3 | 36.4 | 0.304 |
| Corticoids (pre-admission), % | 4.2 | 7.7 | 12.5 | 11.8 | 0 | 0.705 |
| Symptoms | ||||||
|
33.3 | 72.3 | 62.5 | 82.4 | 90.9 | 0.001∗ |
|
41.7 | 64.6 | 50 | 94.1 | 45.5 | 0.001∗ |
|
29.2 | 66.2 | 75 | 100 | 72.7 | 0.001∗ |
|
33.3 | 23.1 | 0 | 29.4 | 36.4 | 0.537 |
| Bilateral pneumonia by CXR, % | 0 | 53.8 | 70 | 93.3 | 100 | 0.001∗ |
| Exitus,% | 0 | 21.5 | 60 | 20 | 27.3 | 0.003∗ |
| ICU, % | 0 | 1.5 | 40 | 100 | 100 | 0.000∗ |
| COVID-19 treatments | ||||||
|
15.5 | 87.3 | 75 | 88.2 | 100 | 0.401 |
|
79.2 | 89.1 | 75 | 70.6 | 90.0 | 0.105 |
|
20.8 | 41.3 | 50 | 70.6 | 90.9 | 0.002∗ |
|
8.3 | 17.9 | 37.5 | 29.4 | 36.4 | 0.705 |
|
0 | 1.6 | 12.5 | 0 | 0 | 0.266 |
|
0 | 0 | 25 | 47.1 | 54.5 | 0.000∗ |
| Biochemical | ||||||
|
135.3(16.6) | 110.8(40.9) | 161.0(45.4) | 157.2(61.7) | 173.6(7.6) | 0.003∗ |
|
33.2(12.8) | 40.8(31.4) | 70.6(37.1) | 55.3(42.7) | 51.09(20.2) | 0.025∗ |
| Inflammatory markers | ||||||
|
1524,2(689.9) | 1120.0(753.6) | 803.7(554.9) | 961.7(392.7) | 654.5(292.8) | 0.002∗ |
|
5.11(6.9) | 8.3(8.7) | 17.2(14.2) | 17.1(9.1) | 23.3(10.8) | 0.000∗ |
|
64.5(34.5) | 76.9(36.0) | 76.0(28.3) | 80.7(29.9) | 76.5(30.9) | 0.594 |
|
430.5(444.9) | 896.2(644.9) | 1406.4(750.4) | 1046.8(640.6) | 1677.7(427.6) | 0.000∗ |
|
1318.7(1399.2 | 1265.5(1319.2) | 5151.7(5453.3) | 2850.0(2365.) | 6231.0(1443.) | 0.011∗ |
|
228.9(84.6) | 301.5(121.05) | 452.3(147.5) | 329.3(103.5) | 430.4(203.9) | 0.000∗ |
| Lipid profile | ||||||
|
155.67(35.2) | 135.3(31.8) | 143.6(50.6) | 116.6(28.4) | 119.6(27.7) | 0.002∗ |
|
36.7(9.5) | 33.3(11.9) | 30.6(10.6) | 29.6(8.9) | 22.1(8.4) | 0.005∗ |
|
89.8(28.5) | 71.4(24.9) | 76.6(37.8) | 98.2(22.3) | 55.1(21.2) | 0.000∗ |
|
136(177) | 147(431) | 195(240) | 167(335) | 189(275) | 0.404 |
|
91.5(34) | 84(90) | 88(54) | 115.5(76) | 91.5(35) | 0.227 |
|
109(78) | 97(108) | 119(99) | 143(64) | 95.5(9) | 0.114 |
OPCD: Obstructive pulmonary chornic disease; HIV: Human immunodeficiency virus; ACE: Angiotensine conversor enzyme, CRP: C reactive protein, ESR: erythrocyte sedimentation rate, LDH: lactate dehydrogenase, TC: total cholesterol, HDL-c: high density lipoprotein, LDL-c: low density lipoprotein, TG: triglyceride, ApoA1: apolipoprotein-A1; ApoB: apolipoprotein-B.